These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19904520)

  • 21. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
    Bornhäuser M; Illmer T; Oelschlaegel U; Schetelig J; Ordemann R; Schaich M; Hänel M; Schuler U; Thiede C; Kiani A; Platzbecker U; Ehninger G
    Clin Cancer Res; 2008 Sep; 14(17):5585-93. PubMed ID: 18765552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
    Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
    Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
    Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
    Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.
    Sumiyoshi R; Tashiro H; Saito S; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2020 Aug; 99(35):e22064. PubMed ID: 32871966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.
    Duncan C; St Martin A; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29067. PubMed ID: 33871892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
    Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ;
    Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
    Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J
    Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
    Fernandez HF; Sun Z; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald G; Ketterling RP; Rowe JM; Lazarus HM; Tallman MS
    Blood; 2011 May; 117(20):5306-13. PubMed ID: 21415269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
    Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
    Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current use and future development of gemtuzumab ozogamicin.
    Larson RA
    Semin Hematol; 2001 Jul; 38(3 Suppl 6):24-31. PubMed ID: 11474494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia.
    Fukushima T; Kawabata H; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Anticancer Res; 2011 May; 31(5):1741-4. PubMed ID: 21617233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.
    Eom KS; Kim HJ; Cho BS; Choi SM; Lee DG; Lee SE; Yahng SA; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Park CW; Min WS
    Leuk Lymphoma; 2011 Dec; 52(12):2321-8. PubMed ID: 22023488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
    Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan CM
    Onkologie; 2004 Jun; 27(3):269-72. PubMed ID: 15249716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.